

A New Broad Acting Antidote For Venom-induced Local Dermal Necrosis



THE UNIVERSITY OF
SYDNEY

[2023-079]

Medical technology



> Pre-Clinical

Problem

Venomous encounters, particularly with snakes, pose a significant global health challenge. Annually, snakebites result in around 138,000 deaths and 400,000 severe injuries, with the highest impact in Africa and Asia. The socio-economic impact is profound, especially in Southeast Asia, where the costs related to snakebites reach about \$2.5 billion USD.

Marine stings also pose a risk; bluebottles cause around 10,000 stings each summer in Australia, and sea nettles, found across various oceans, deliver stings that can range from mildly to moderately painful, with severe cases sometimes requiring medical intervention. Current anti-venom treatments have limitations such as species-specificity and storage requirements, highlighting the need for a universally effective antidote for venom-related injuries.

Solution

Our team have developed a novel strategy for treating or preventing injuries caused by venom, including tissue damage and skin irritation. It involves administering a composition containing an active anti-venom agent. This treatment is being developed in multiple forms, such as topical creams, sprays and injectables targeting a range of venomous sources. The approach is broad-acting and designed to neutralise various toxins found in certain venoms. The anti-venom treatment is intended for prompt application following venom exposure and is adaptable for use against venom from various origins, including different species of snakes along with blue bottles and sea nettles.

Intellectual Property Status

Provisional patent application.

Commercial Opportunity

This is an opportunity to acquire an innovative anti-venom treatment, that offers a broad-spectrum solution for neutralising toxins from diverse venomous sources, including snakes and marine life and providing immediate post-exposure intervention to reduce tissue damage and irritation.

Inventors

Professor Graham Neely, Felicity Shu Yin Chung, Nicholas Casewell, Tian Du

Potential Commercial Applications

Creams, sprays, and injectables, for broad-spectrum solution for neutralising toxins from diverse venomous source.

Contact Commercialisation Office

Name: Emma-Louise Hunsley

Position: Commercialisation Manager - Sydney Biomedical Accelerator

Email: emma-louise.hunsley@sydney.edu.au | Phone: 0437468275

sydney.edu.au/innovation-and-enterprise